Cammu Guy, Lecomte Patrick, Casselman Filip, Demeyer Ignace, Coddens José, Morias Karl, Deloof Thierry, Nobels Frank, Van Crombrugge Paul, Foubert Luc
Department of Anesthesiology and Critical Care Medicine, OLV Clinic, 9300 Aalst, Belgium.
J Clin Anesth. 2007 Feb;19(1):37-43. doi: 10.1016/j.jclinane.2006.05.022.
To investigate whether preinduction glucose is an important predictor for perioperative insulin management in patients undergoing cardiac surgery.
Prospective cohort study.
Large community hospital.
80 consecutive patients scheduled for cardiac surgery.
Patients were subdivided into those with a preinduction blood glucose of 110 mg/dL or lower with or without history of diabetes (group 1) and those with a preinduction blood glucose of above 110 mg/dL with or without history of diabetes (group 2). In group 1, there were no known diabetics. In group 2, 31% (11/35) had diabetes (group 2DM), while 24/35 (69%) did not (group 2NDM). An insulin infusion was started intraoperatively and adjusted according to a strict protocol in order to maintain normoglycemia (80-110 mg/dL) until discharge from intensive care.
In patients with preinduction glucose above 110 mg/dL, whether or not previously treated for diabetes, perioperative insulin requirements were higher, and intraoperative insulin management was more difficult than in those with lower preinduction glucose. In patients with a preinduction glucose above 110 mg/dL, hospital stay was longer, and inhospital mortality was significantly higher than in those with lower preinduction glucose. Multivariate analyses showed that preinduction glycemia was a good predictor of intraoperative insulin consumption, as was the body mass index (BMI) for intensive care and total insulin needs.
In cardiac surgical patients with a preinduction glucose above 110 mg/dL, even if diabetes was not previously suspected, perioperative insulin requirements were higher, and intraoperative insulin management is more difficult than in those with a preinduction glucose 110 mg/dL or lower. Preinduction glycemia and BMI are good predictors of perioperative insulin management. Preinduction glycemia above 110 mg/dL predicts difficult perioperative glucose control and, moreover, that a preinduction blood glucose of 110 mg/dL or lower is associated with less insulin need.
探讨诱导前血糖水平是否是心脏手术患者围手术期胰岛素管理的重要预测指标。
前瞻性队列研究。
大型社区医院。
80例连续接受心脏手术的患者。
患者被分为诱导前血糖水平为110mg/dL及以下且有无糖尿病史的患者(第1组),以及诱导前血糖水平高于110mg/dL且有无糖尿病史的患者(第2组)。第1组中无已知糖尿病患者。第2组中,31%(11/35)患有糖尿病(第2组糖尿病患者),而24/35(69%)没有糖尿病(第2组非糖尿病患者)。术中开始胰岛素输注,并根据严格方案进行调整,以维持血糖正常(80 - 110mg/dL),直至从重症监护病房出院。
诱导前血糖水平高于110mg/dL的患者,无论之前是否接受过糖尿病治疗,围手术期胰岛素需求量更高,术中胰岛素管理比诱导前血糖水平较低的患者更困难。诱导前血糖水平高于110mg/dL的患者住院时间更长,住院死亡率显著高于诱导前血糖水平较低的患者。多因素分析表明,诱导前血糖水平是术中胰岛素消耗量的良好预测指标,体重指数(BMI)对重症监护和总胰岛素需求也是如此。
在诱导前血糖水平高于110mg/dL的心脏手术患者中,即使之前未怀疑患有糖尿病,围手术期胰岛素需求量也更高,术中胰岛素管理比诱导前血糖水平为110mg/dL及以下的患者更困难。诱导前血糖水平和BMI是围手术期胰岛素管理的良好预测指标。诱导前血糖水平高于110mg/dL预示着围手术期血糖控制困难,此外,诱导前血糖水平为110mg/dL及以下与胰岛素需求较少相关。